NewAmsterdam Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . NewAmsterdam Pharma
NAMS Stock   32.41  0.76  2.40%   
NewAmsterdam Pharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing NewAmsterdam Pharma's valuation are provided below:
Gross Profit
35.2 M
Market Capitalization
3.6 B
Enterprise Value Revenue
81.8925
Revenue
35.2 M
Earnings Share
(2.04)
There are over one hundred nineteen available fundamental ratios for NewAmsterdam Pharma, which can be analyzed over time and compared to other ratios. All traders should check NewAmsterdam Pharma's last-minute fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction.

NewAmsterdam Pharma Total Revenue

35.72 Million

Check NewAmsterdam Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NewAmsterdam Pharma's main balance sheet or income statement drivers, such as Net Interest Income of 20.4 M, Interest Income of 20.4 M or Depreciation And Amortization of 136.4 K, as well as many indicators such as Price To Sales Ratio of 32.1, Dividend Yield of 0.0 or PTB Ratio of 1.82. NewAmsterdam financial statements analysis is a perfect complement when working with NewAmsterdam Pharma Valuation or Volatility modules.
  
Build AI portfolio with NewAmsterdam Stock
Check out the analysis of NewAmsterdam Pharma Correlation against competitors.
For more information on how to buy NewAmsterdam Stock please use our How to Invest in NewAmsterdam Pharma guide.

NewAmsterdam Pharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1 B994.3 M313.8 M
Slightly volatile
Short and Long Term Debt Total383 K403.2 K7.6 M
Slightly volatile
Other Current Liabilities115.8 M110.3 M22.1 M
Slightly volatile
Total Current Liabilities129.1 M123 M27 M
Slightly volatile
Total Stockholder Equity914.7 M871.1 M277.7 M
Slightly volatile
Property Plant And Equipment Net812.6 K774 K168.4 K
Slightly volatile
Accounts Payable9 M5.5 M3.3 M
Slightly volatile
Cash931.9 M887.5 M204.4 M
Slightly volatile
Non Current Assets Total1 M1.1 M89.6 M
Slightly volatile
Cash And Short Term Investments1 B959.3 M216.7 M
Slightly volatile
Common Stock Shares Outstanding113.9 M108.5 M37.1 M
Slightly volatile
Liabilities And Stockholders Equity1 B994.3 M313.8 M
Slightly volatile
Non Current Liabilities Total172.7 K181.8 K9.2 M
Slightly volatile
Other Current Assets6.5 M9.1 M3 M
Slightly volatile
Other Stockholder Equity437 M850.5 M195.5 M
Slightly volatile
Total Liabilities129.3 M123.2 M36.2 M
Slightly volatile
Net Invested Capital914.7 M871.1 M203.2 M
Slightly volatile
Property Plant And Equipment Gross812.6 K774 K172.2 K
Slightly volatile
Short and Long Term Debt9.3 M10.5 M11.4 M
Slightly volatile
Total Current Assets1 B992.9 M224.2 M
Slightly volatile
Capital Stock11.5 M12.1 M44.6 M
Pretty Stable
Short Term Debt210.3 K221.4 K7.6 M
Slightly volatile
Common Stock11.5 M12.1 M82.6 M
Slightly volatile
Property Plant Equipment111.1 K218.5 K71.9 K
Slightly volatile
Current Deferred Revenue8.7 M6.9 M5.1 M
Slightly volatile
Other Assets23.9 K25.1 K514.6 K
Slightly volatile
Net Receivables25.7 M24.5 M7.9 M
Slightly volatile
Accumulated Other Comprehensive Income3.8 M5.1 M1.8 M
Slightly volatile
Good Will186.5 K209.8 K229 K
Slightly volatile
Intangible Assets334.4 K614.1 K256.3 K
Slightly volatile

NewAmsterdam Pharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization136.4 K129.9 K26.8 K
Slightly volatile
Selling General Administrative85.1 M81 M18.6 M
Slightly volatile
Selling And Marketing Expenses4.9 M4.7 M1.2 M
Slightly volatile
Other Operating Expenses267.9 M255.1 M68 M
Slightly volatile
Research Development94.9 M174.1 M44.1 M
Slightly volatile
Total Operating Expenses267.9 M255.1 M68 M
Slightly volatile
Reconciled Depreciation136.4 K129.9 K30.9 K
Slightly volatile
Cost Of Revenue66.7 K129.9 K35.3 K
Slightly volatile

NewAmsterdam Pharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow411.1 M391.5 M100.8 M
Slightly volatile
Depreciation136.4 K129.9 K26.8 K
Slightly volatile
Other Non Cash Items99 M94.3 M18.2 M
Slightly volatile
Capital Expenditures811.4 K772.8 K158.9 K
Slightly volatile
Total Cash From Financing Activities796.4 M758.4 M167.8 M
Slightly volatile
End Period Cash Flow931.9 M887.5 M209.8 M
Slightly volatile
Change To Liabilities5 M9.5 M3.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio32.147.913.2074
Slightly volatile
PTB Ratio1.822.881.8163
Slightly volatile
Days Sales Outstanding87.7615464.3654
Slightly volatile
Book Value Per Share7.147.237.6917
Pretty Stable
Average Payables5.2 M8.5 M5 M
Slightly volatile
Stock Based Compensation To Revenue0.670.660.2549
Slightly volatile
Capex To Depreciation10.746.8411.5513
Slightly volatile
PB Ratio1.822.881.8163
Slightly volatile
Sales General And Administrative To Revenue1.181.390.5445
Slightly volatile
Research And Ddevelopement To Revenue4.132.991.9258
Slightly volatile
Capex To Revenue0.01390.01330.0042
Slightly volatile
Cash Per Share6.587.963.3196
Slightly volatile
Intangibles To Total Assets4.0E-46.0E-45.0E-4
Slightly volatile
Net Debt To EBITDA4.432.872.1807
Slightly volatile
Current Ratio6.747.277.9508
Very volatile
Tangible Book Value Per Share7.137.227.6895
Pretty Stable
Receivables Turnover2.342.466.577
Slightly volatile
Shareholders Equity Per Share7.147.237.6917
Pretty Stable
Debt To Equity0.00127.0E-40.0025
Slightly volatile
Capex Per Share0.00340.00640.0024
Slightly volatile
Revenue Per Share0.530.564.2432
Slightly volatile
Interest Debt Per Share0.00520.00550.0309
Slightly volatile
Debt To Assets0.0016.0E-40.0021
Slightly volatile
Operating Cycle87.7615464.3654
Slightly volatile
Price Book Value Ratio1.822.881.8163
Slightly volatile
Ebt Per Ebit1.751.231.4426
Slightly volatile
Company Equity Multiplier0.921.031.0988
Pretty Stable
Total Debt To Capitalization0.00127.0E-40.0025
Slightly volatile
Debt Equity Ratio0.00127.0E-40.0025
Slightly volatile
Quick Ratio6.747.277.9508
Very volatile
Net Income Per E B T1.11.151.0148
Slightly volatile
Cash Ratio6.16.56.3808
Slightly volatile
Cash Conversion Cycle87.7615464.3654
Slightly volatile
Days Of Sales Outstanding87.7615464.3654
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.80.90.9829
Slightly volatile
Price To Book Ratio1.822.881.8163
Slightly volatile
Fixed Asset Turnover73.9677.86531
Slightly volatile
Debt Ratio0.0016.0E-40.0021
Slightly volatile
Price Sales Ratio32.147.913.2074
Slightly volatile
Asset Turnover0.110.06060.1796
Slightly volatile
Price Fair Value1.822.881.8163
Slightly volatile

NewAmsterdam Pharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.3 B2.2 B706.6 M
Slightly volatile

NewAmsterdam Fundamental Market Drivers

NewAmsterdam Upcoming Events

29th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
29th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About NewAmsterdam Pharma Financial Statements

NewAmsterdam Pharma shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although NewAmsterdam Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in NewAmsterdam Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on NewAmsterdam Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue6.9 M8.7 M
Total Revenue52.4 M35.7 M
Cost Of Revenue129.9 K66.7 K
Stock Based Compensation To Revenue 0.66  0.67 
Sales General And Administrative To Revenue 1.39  1.18 
Research And Ddevelopement To Revenue 2.99  4.13 
Capex To Revenue 0.01  0.01 
Revenue Per Share 0.56  0.53 
Ebit Per Revenue(4.45)(4.67)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for NewAmsterdam Stock Analysis

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY